Saturday 17 October 2026
Export APUS’s income statement to Excel — free account
Apimeds Pharmaceuticals US, Inc.
APUS Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS fell 352.7%, free cash flow fell 67.9% and total debt rose 2,468.3%, each against the same quarter a year earlier.
4.04
0.35
−7.97%
Follow APUS
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 0.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 40.31 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 2 | 2 | 7 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | (1) | (1) | (6) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | (1) | (1) | (6) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | (1.69) | (1.80) | (5.50) | |||||
| Cash flow | — | — | — | — | — | — | — | (1.37) | (0.93) | (8.20) | |||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.00 | (0.05) | |||||
| Free cash flow | — | — | — | — | — | — | — | (1.37) | (0.93) | (8.25) | |||||
| Book value | — | — | — | — | — | — | — | 0.07 | (1.72) | 140.92 | |||||
| Shares, m | — | — | — | — | — | — | — | 0 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (1) | (1) | (9) | ||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | (1) | (1) | (9) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 0 | (1) | 3 | ||||
| Total debt | — | — | — | — | — | — | — | 0 | 0 | 7 | |||||
| Net debt | — | — | — | — | — | — | — | 0 | 0 | (5) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | 0 | (1) | 153 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (638.79) | (7.31) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | (5.00) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 209.62 | (7.90) | |||||
Negative figures in brackets.
Charts ten years each
Apimeds Pharmaceuticals US, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BGXXQ Bright Green Corporation | $13.9M | — (loss-making) | — | — | n/m | −1.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BFRI Biofrontera Inc. | $12.6M | — (loss-making) | — (loss-making) | +32.92% (above 0%: growing) | n/m | +45.57% (above 0%: growing) | 79.92% | (4.37%) | Compare |
| INM InMed Pharmaceuticals Inc. | $7.3M | — (loss-making) | — | −26.22% (below 0%: shrinking) | n/m | −40.43% (below 0%: shrinking) | 22.46% | 0.00% | Compare |
| APUS Apimeds Pharmaceuticals US, Inc. | $6.6M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | |
| SNOA Sonoma Pharmaceuticals, Inc. | $5.5M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| GELS Gelteq Limited | $4.6M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | Compare |
| RDHL Redhill Biopharma Ltd. | $4.4M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| YCBD cbdMD, Inc. | $4.0M | 41.2× | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| AKAN Akanda Corp. | $3.5M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| Median of peers | $5.1M | — | — | +20.55% | — | −20.80% | 22.46% | 0.00% |
Apimeds Pharmaceuticals US, Inc. (APUS) key facts
- Apimeds Pharmaceuticals US, Inc. (APUS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, APUS traded at $4.04, a market capitalization of $6.6 million.
- Return on equity was −7.90% and debt-to-equity 0.08.